XtalPi Holdings Limited (HKG:2228)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 36.68B |
| Revenue (ttm) | 283.53M |
| Net Income (ttm) | -1.61B |
| Shares Out | 4.02B |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 498,724,837 |
| Average Volume | 194,608,992 |
| Open | 8.31 |
| Previous Close | 8.18 |
| Day's Range | 8.13 - 9.50 |
| 52-Week Range | 3.05 - 16.20 |
| Beta | n/a |
| RSI | 81.42 |
| Earnings Date | Aug 28, 2025 |
About XtalPi Holdings
XtalPi Holdings Limited, an investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally. The company offers XMolGen, an AI small molecule drug discovery smart computation platform; XtalFold, an antibody-antigen complex structure prediction platform which predicts the antibody-antigen complex structure and identifies key interaction sites; and Xtalgazer, a new generation of drug crystallization research and development platform which predict the physicoch... [Read more]
Financial Performance
In 2024, XtalPi Holdings's revenue was 266.43 million, an increase of 52.75% compared to the previous year's 174.42 million. Losses were -1.52 billion, -20.78% less than in 2023.
Financial numbers in CNY Financial StatementsNews
Chinese drug developer XTalPi surges on US$6 billion deal
Shares of Shenzhen-based AI-powered drug researcher XTalPi jumped as much as 23 per cent after it signed a US$6 billion deal with a firm founded by a Harvard University chemist with a reputation as a ...
Chinese AI and robotics start-ups from AgiBot to XtalPi respond to Xi’s self-reliance call
The Chinese president met representatives from several AI and robotics start-ups during a visit to Shanghai.